Cardiac parasympathetic control has prognostic significance in heart failure, but the control mechanisms of this system remain poorly defined. We have demonstrated previously a facilitatory role for nitric oxide (NO) in the parasympathetic control of heart rate in young healthy human subjects. In view of the complex abnormalities of regional NO activity observed in chronic heart failure, we now aim to establish if this mechanism is active in subjects with this condition. Groups of 12 heart failure patients [NYHA class II-III ; mean age 52 years (range 38-67 years)] and 12 age/sex-matched healthy control subjects [mean age 50 years (range 36-62 years)] were studied. Heart rate variability and baroreflex sensitivity were measured during inhibition of endogenous NO production with N G -monomethyl-L-arginine (L-NMMA ; 3 mg:h − 1 :kg − 1 ) and during administration of an equipressor dose of the control vasoconstrictor phenylephrine (12-36 µg:h − 1 :kg − 1 ). Basal levels of nitratejnitrite were measured in the plasma as an indication of systemic NO production. In the heart failure patients, despite an equal rise in blood pressure with both drugs, high-frequency indices of heart rate variability increased less with L-NMMA than with phenylephrine : RMSSD (root mean square of successive RR-interval differences) increased by 4p2 compared with 26p8 ms (P 0n001) and high-frequency power increased by 97p62 compared with 1372p861 ms 2 (P 0n001). The increases in cross-spectral baroreflex sensitivity were also lower with L-NMMA than with phenylephrine [high-frequency α-index, 2n2p1n3 and 12n6p3n8 ms/mmHg respectively (P 0n001) ; low-frequency α-index, 1n3p0n9 and 4n3p1n7 ms/mmHg respectively (P 0n05)]. Healthy subjects showed a similar discrepancy in the response of high-frequency indices of heart rate variability to the two drugs, although baroreflex sensitivity responses were significantly different only for the high-frequency α-index. Levels of plasma nitratejnitrite were significantly higher in the heart failure patients compared with controls. These data demonstrate that baroreflex-mediated cardiac parasympathetic activation in human heart failure, as in health, is dependent upon endogenous NO synthesis.
INTRODUCTION
Chronic heart failure is characterized by abnormalities of cardiac autonomic function, including high levels of sympathetic activity, impaired parasympathetic control and subnormal arterial baroreflex gain [1, 2] . The degree of impairment of parasympathetic control as measured by heart rate variability (HRV) and baroreflex sensitivity (BRS) has been shown to be a powerful and independent indicator of an adverse prognosis [3] . It seems likely that, as with excess sympathetic activity, impaired parasympathetic control contributes actively to disease pro-gression and mortality in chronic heart failure [2, 3] . Despite this, the control of cardiac parasympathetic activity is poorly understood, particularly in cardiac disease states such as chronic heart failure.
Animal data suggest that nitric oxide (NO) may play an important role as a neuromodulator within central and peripheral neuronal pathways that regulate cardiovascular autonomic activity. The overall effect of NO generation within these sites appears to be parasympathetic activation and sympathetic withdrawal [4] [5] [6] [7] [8] [9] [10] . We have demonstrated previously that both NO synthase (NOS) inhibition and exogenous NO donation modulate the parasympathetic control of heart rate in conscious healthy human volunteers in a manner consistent with NO promoting levels of cardiac parasympathetic control [11] . It is difficult to predict the extent to which this mechanism might exist in heart failure, because of the complex abnormalities of regional NO pathway activity that occur in this condition. Nitrergic modulation of cardiac parasympathetic control may be preserved or even increased if effected by the systemic overproduction of NO [12] caused by cytokine-mediated induction of inducible NOS (iNOS) within the circulation and myocardium [13, 14] . Alternatively, it may be decreased if mediated by cardiac endothelial NOS (eNOS) or neuronal NOS (nNOS) within autonomic central nervous sites, as there is evidence that expression of these isoforms is reduced at these sites in heart failure [14, 15] . To date, there have been no human studies examining the role of NO in the modulation of cardiac parasympathetic control in heart failure.
METHODS
To investigate whether NO contributes to the regulation of cardiac parasympathetic control in patients with moderate to severe heart failure, we have investigated the effects of systemic NOS inhibition with N G -monomethyl-L-arginine (L-NMMA) on non-invasive markers of parasympathetic heart rate control, namely HRV and BRS. The inhibition of vascular NO production by L-NMMA results in a pressor response and consequent baroreflex activation. This confounding autonomic action was controlled for by comparing the results obtained during L-NMMA infusion with those obtained during an equipressor infusion of a control vasoconstrictor, phenylephrine, a specific α " -adrenergic agonist without direct effects on NO pathway activity.
Subjects
Patients with stable heart failure (no changes in medical therapy and no hospital admissions within the last 2 months) were recruited from outpatient clinics. Age\sex-matched healthy control subjects were recruited from staff at our institution. Patients were in sinus rhythm, normotensive (blood pressure 140\90 mmHg), with normal renal function (serum creatinine 130 µmol\l) and had an echocardiographic ejection fraction of 40 % at study entry. No patient was receiving nitrate therapy, and β-blockers were omitted for 72 h prior to each study visit. Other medications were held constant for the duration of the patients ' enrolment. Control subjects had no evidence of cardiovascular disease on history, physical examination or ECG. All subjects were asked to abstain from food and drink for at least 2 h prior to the study, and from caffeine and alcohol for 24 h. A dietary history was taken to estimate dietary nitrate intake at the time of study [16] . The protocol conformed with the Declaration of Helsinki (1989) of the World Medical Association, and was approved by the ethics committee of our institution. All subjects gave written consent.
Experimental protocol
Protocols were of a single-blind, random-order, crossover design. All subjects had a preliminary acclimatization visit, where they were trained to breathe to an audio signal set close to the individual's resting respiratory rate. Each patient was then randomly assigned to receive either an intravenous infusion of L-NMMA (3 mg:h −" :kg −" ) or a control infusion of the pressor agent phenylephrine (12-36 µg:h −" :kg −" ) during the first of two studies. The remaining agent was given during a separate study visit 7-14 days later.
Studies were performed at a uniform time of day and at ambient temperature (24p1 mC). Subjects rested semisupine, and signals from a three-lead ECG, a Portapres device (TNO Biomedical Instrumentation) recording continuous arterial pressure and a strain gauge attached around the subject's chest quantifying respiratory excursion were recorded digitally at 500 Hz. A venous cannula was inserted into an antecubital vein for drug administration, after which subjects rested for 30 min before selected periods for all three signals were stored to disk during breathing at the predetermined frequency. Two 5 min recordings were acquired at baseline during a 30 min normal saline infusion, and a further two recordings were acquired during the vasoactive infusion once a steady mean heart rate and arterial pressure were achieved. Infusion rates were titrated to achieve a target increment of 5-10 mmHg in mean arterial pressure, as assessed from a continuously updated 60 s integrated mean of the Portapres signal and by automated intermittent arm cuff sphygmomanometry.
Data analysis
The investigator performing the analysis was blinded to both the subject and the vasoactive agent under study. All ECG series were reviewed manually, and those containing more than 2 % ectopic beats were excluded. Less frequent ectopics were replaced by interpolation from the previous and subsequent sinus intervals. HRV and BRS were analysed off-line using Lab-View 5.0 software.
HRV
Standard time-domain measures of the S.D. of RRinterval values, expressing overall variability, and RMSSD (root mean square of successive RR-interval differences), reflecting high-frequency (' beat to beat ') variation mediated principally by the vagus nerve [17] , were employed. Frequency-domain analysis was performed on stationary RR-interval series using autoregressive modelling (Burg algorithm) to determine spectral powers at low frequency (LF ; centred at " 0n1 Hz) and at high frequency (HF ; corresponding to the observed respiratory frequency), as described previously [11] .
BRS
Spontaneous BRS was assessed by fast Fourier transformation cross-spectral analysis of RR interval and systolic blood pressure variability using methods that have been described previously [11] . The α-index was derived as the transfer function of systolic power into RR-interval power for both the HF (α-HF) and LF (α-LF) bands, provided that the squared coherence between the two signals was 0n5.
Measurement of plasma combined nitratejnitrite (NO x ) concentration
Plasma concentrations of NO x , representing stable breakdown products of NO, were measured as a surrogate marker of NO formation. Nitrate was first reduced to nitrite by enzymic conversion with nitrate reductase. Following deproteinization, plasma NO x concentrations were measured using the Griess reaction [18] . To minimize intra-subject variability secondary to changes in dietary nitrate consumption, values are quoted as the mean of readings obtained on each of the two study days.
Statistical analysis
Haemodynamic data and indices of HRV and BRS were expressed as the mean of the two recording periods for each infusion. Data for mean arterial pressure, RR interval and plasma NO x were compared by a two-tailed paired Student's t test. Differences between groups for indices of HRV and BRS were determined using the Wilcoxon signed rank test for paired data. Statistical significance was taken as P 0n05, and values are expressed as meanspS.E.M.
RESULTS
A total of 16 heart failure patients were recruited, of whom four were excluded at the initial training visit due to a high incidence of ventricular ectopy. The remaining 12 patients comprised ten men and two women (mean age 52 years ; range 38-67 years) with chronic heart failure (NYHA class II-III) due to coronary artery disease (seven patients) or idiopathic dilated cardiomyopathy (five patients). The mean ejection fraction (assessed by two-dimensional M-mode trans-thoracic echocardiography) at the time of study was 27 % (range 15-33 %). All patients were taking angiotensin-converting enzyme (ACE) inhibitors and loop diuretics, five were taking digoxin, two amiodarone and one spironolactone. Three patients were taking carvedilol, which was omitted for 72 h before the studies. Twelve healthy controls were also enrolled, comprising ten men and two women (mean age 50 years ; range 36-62 years). None were taking any medication.
The frequency of metronomic breathing was within the range 0n18-10n26 Hz for both study groups. When comparing baseline measurements prior to the administration of L-NMMA with those prior to the administration of phenylephrine, no significant differences were seen in mean arterial pressure, RR interval or indices of HRV or BRS within each of the two study groups (Table 1) .
In the heart failure group, infusion of L-NMMA and phenylephrine resulted in equal rises in mean arterial pressure (Table 2) . However, the increase in mean RR interval was markedly lower with L-NMMA than with phenylephrine. The increases in all indices of HF HRV in both the time and frequency domains (i.e. RMSSD and HF power) were significantly smaller in response to L-NMMA than in response to the equipressor phenylephrine infusion (Table 2, Figure 1) . The LF\HF ratio, a proposed (although not universally accepted) indicator of sympathetic relative to parasympathetic influence, was unchanged with L-NMMA, in contrast with the significant fall seen with phenylephrine infusion. Increases in cross-spectral BRS were lower during L-NMMA infusion than during phenylephrine infusion. This was true for both α-HF and α-LF ( Table 2) .
The healthy control subjects had higher values at baseline for mean arterial pressure, mean RR interval, α-HF and the majority of HRV indices in comparison with the patient group (Table 1) . Again, the rise in mean arterial pressure was well matched between the L-NMMA and phenylephrine infusions, whereas the mean RR interval tended to lengthen less with L-NMMA (P l 0n1). The majority of indices of parasympathetic cardiac control showed a significantly lower rise with L-NMMA than with phenylephrine (RMSSD, HF power and α-HF ; Table 2 ).
The patient and control groups did not differ significantly in terms of estimated dietary nitrate intake (57p4 and 72p9 mg\day respectively ; P l 0n17). Plasma NO x levels were significantly higher in the heart failure patients than in the healthy controls (28n6p13n6 and 19n3p3n3 µmol\l respectively ; P 0n05). 
DISCUSSION
These data demonstrate for the first time that endogenous NO synthesis remains an important vagotonic modulator of human cardiac autonomic control, not only in health but also in heart failure. This is revealed by the lack of any significant rise in BRS or in HF indices of HRV -both well validated indicators of cardiac parasympathetic control [17] -during baroreflex loading with a NOS inhibitor in patients with heart failure. In contrast, there was a notable rise in these indices during an equipressor infusion of a control vasoconstrictor. This suggests an impaired ability to increase cardiac parasympathetic activity during baroreflex stimulation when NO synthesis is inhibited. Similar results were seen in agematched healthy control subjects. These results are in agreement with our previous findings in a population of young healthy volunteers, where we demonstrated a vagotonic action not only for endogenous NO but also for exogenous NO donors [11] . Spieker et al. [19] have also recently demonstrated an important role for NO in the baroreflex control of heart rate in healthy human volunteers. Animal data also confirm a vagotonic action of NO. Discrete neuronal populations containing NOS are distributed widely throughout the peripheral and central components of the cardiac baroreflex pathway [20] . Functionally, NO has been shown to increase neuronal activity within central sites regulating parasympathetic outflow to the heart [4, 9] . Peripherally, NO potentiates the bradycardic effects of parasympathetic stimulation [5, 6] and also enhances the ability of the efferent vagus to antagonize sympathetic cardiac responses, with both preand post-synaptic mechanisms postulated [10] . Consistent with these data, nNOS knockout mice display reduced cardiac parasympathetic tone [7] .
How can our finding of a preserved vagotonic influence for NO in heart failure be interpreted in the The spectra were obtained for a 38-year-old male with idiopathic dilated cardiomyopathy (NYHA class II ; ejection fraction 32 %) displaying typical data at baseline (A) and at steady state during equipressor infusions of L-NMMA (B) and phenylephrine (C). The area under the HF peak, an index of cardiac parasympathetic control, is visibly smaller with L-NMMA than with phenylephrine. PSD, power spectral density.
light of the known abnormalities of regional NO pathway activity in this condition ? The previous animal and human data are confined to healthy models and thus reflect primarily the actions of constitutive NOS isoforms (eNOS and nNOS). While these isoforms would have been active in our healthy control subjects, they appear to have reduced expression in heart failure. Although not a universal finding in heart failure of all aetiologies, cardiac eNOS expression has been shown to be impaired in end-stage ischaemic and dilated cardiomyopathies [14] . Rats with experimental heart failure show reduced nNOS mRNA at brain sites concerned with cardiovascular autonomic processing [15] . Impaired constitutive NOS activity at these sites would be expected to reduce, rather than preserve, the role of NO in facilitating cardiac parasympathetic activation in our heart failure patients.
It appears more likely that our results can be explained by changes in iNOS expression. This isoform is not expressed in health, but in human heart failure there is a well documented cytokine-mediated induction of iNOS within the circulation and myocardium, leading to the sustained release of large amounts of NO [12] [13] [14] . In agreement with this, we found that the systemic production of NO was not only preserved but actually increased in heart failure, with the demonstration of higher levels of plasma NO x in patients compared with healthy controls, despite similar levels of dietary nitrate intake. Since the expression of iNOS in the failing myocardium has been shown to include the right atrium, it is likely that NO bioavailability in the region of the sino-atrial node is increased [13] , providing one possible mechanism by which NO generated by iNOS may interact with autonomic signalling to the heart. The hypothesis that preserved cardiac autonomic activity of NO in heart failure is attributable mainly to cardiac iNOS induction, offsetting potential deficiencies in constitutive NOS signalling, appears attractive but further research is needed. For instance, changes in nNOS activity in human heart failure have not been studied comprehensively. It is not known whether effects on central nNOS expression conform to those seen in the brains of rats with heart failure [15] , or indeed what changes occur within the peripheral nervous system. There is some evidence that nNOS expression is increased within nerve fibres in the left ventricle of rats with ischaemic heart failure [21] . Furthermore, an nNOS-like isoform has been described in the cardiac sarcoplasmic reticulum, and the expression of this in heart failure has not been studied [22] .
The present study has some limitations. First, we used a non-specific NOS inhibitor to examine the influence of endogenous NO on autonomic modulation in conscious subjects with intact baroreflexes. This design does not enable us to actively determine the site of NO generation nor the isoform of NOS responsible for the observed effects. Furthermore, the lack of a specific HRV marker of sympathetic activity makes it difficult to comment on the role that a nitrergic influence on cardiac sympathetic tone would have had on our results.
β-Blockers were withheld in view of their powerful effects on cardiac autonomic control ; their profound bradycardic effect might have limited that elicited by baroreflex loading and therefore masked differences in the responses to phenylephrine and L-NMMA. Ethical considerations prohibited us from discontinuing other established medications, some of which may have had an autonomic influence. Both digoxin (five patients) and amiodarone (two patients) were continued, but the dose of these agents was unchanged during the study period and the crossover design of the study ensured that the influence of these drugs on autonomic control was identical in both limbs. However, ACE inhibitor therapy (which was taken by all patients) may have had a complex influence on our results. Chronic ACE inhibition is known to exert a powerful cardiac vagotonic influ-ence [23] . Furthermore, it has been shown to increase eNOS expression and NO release in the vasculature of rats and the atria of human patients, as well as leading to recruitment of human nNOS, possibly via the accumulation of endogenous kinins [24] [25] [26] . Despite the difficulty in predicting the impact of these effects in our study, the results are perhaps more notable for the fact that the observed reliance upon NO generation for cardiac parasympathetic activation in our heart failure population was additional to the vagotonic effects of ACE inhibitors.
In conclusion, the present study provides the first demonstration of a role for NO in the control of cardiac parasympathetic function in human heart failure. The advent of novel methods of manipulation of NO pathway activity may provide a means of correcting the impairment of cardiac parasympathetic control observed in this condition, with potentially beneficial prognostic consequences.
